{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:47:13Z","timestamp":1772470033634,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cathepsin K (CatK) is a lysosomal protease with collagenolytic activity, and its secretion by osteoclasts is responsible for degrading organic bone matrix. People with pathologic bone resorption have higher circulating CatK concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>Canine osteosarcoma (OS) cells will possess CatK, and its secretion will be cytokine inducible. Circulating CatK concentrations will be increased in dogs with OS, and will be a surrogate marker of bone resorption.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Fifty-one dogs with appendicular OS and 18 age- and weight-matched healthy control dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a prospective study, expressions of CatK mRNA and protein were investigated in OS cells. The inducible secretion and proteolytic activity of CatK from OS cells was assessed in vitro. Serum CatK concentrations were quantified in normal dogs and dogs with OS and its utility as a bone resorption marker was evaluated in dogs with OS treated with palliative radiation and antiresorptive agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Canine OS cells contain preformed CatK within cytoplasmic vesicles. In OS cells, TGF\u03b21 induced the secretion of CatK, which degraded bone-derived type I collagen in vitro. CatK concentrations were higher in dogs with OS than healthy dogs (11.3\u00a0\u00b1\u00a05.2\u00a0pmol\/L versus 8.1\u00a0\u00b1\u00a05.0\u00a0pmol\/L, P\u00a0= .03). In a subset of dogs with OS, pretreatment CatK concentrations gradually decreased after palliative radiation and antiresorptive treatment, from 9.3\u00a0\u00b1\u00a03.2\u00a0pmol\/L to 5.0\u00a0\u00b1\u00a03.1\u00a0pmol\/L, P\u00a0= .03.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Canine OS is associated with pathologic bone resorption, and CatK inhibitors might aid in the management of canine OS-related malignant osteolysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2011.00834.x","type":"journal-article","created":{"date-parts":[[2011,12,15]],"date-time":"2011-12-15T05:13:58Z","timestamp":1323926038000},"page":"126-134","source":"Crossref","is-referenced-by-count":11,"title":["Cathepsin K Expression and Activity in Canine Osteosarcoma"],"prefix":"10.1093","volume":"26","author":[{"given":"J.M.","family":"Schmit","sequence":"first","affiliation":[{"name":"of Veterinary Clinical Medicine From the Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.","family":"Pondenis","sequence":"additional","affiliation":[{"name":"of Veterinary Clinical Medicine From the Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Barger","sequence":"additional","affiliation":[{"name":"University of Illinois Department of Pathobiology, , Urbana, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.B.","family":"Borst","sequence":"additional","affiliation":[{"name":"North Carolina State University Department of Population Health and Pathobiology, , Raleigh, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.D.","family":"Garrett","sequence":"additional","affiliation":[{"name":"of Veterinary Clinical Medicine From the Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Wypij","sequence":"additional","affiliation":[{"name":"of Veterinary Clinical Medicine From the Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.L.","family":"Neumann","sequence":"additional","affiliation":[{"name":"of Veterinary Clinical Medicine From the Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.M.","family":"Fan","sequence":"additional","affiliation":[{"name":"of Veterinary Clinical Medicine From the Department"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,1,1]]},"reference":[{"key":"2026020303573369600_jvim834-bib-0001","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1515\/BC.2004.132","article-title":"Cysteine cathepsins in human cancer","volume":"385","author":"Jedeszko","year":"2004","journal-title":"Biol Chem"},{"key":"2026020303573369600_jvim834-bib-0002","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.4161\/cc.3.12.1289","article-title":"Multiple roles for cysteine cathepsins in cancer","volume":"3","author":"Joyce","year":"2004","journal-title":"Cell Cycle"},{"key":"2026020303573369600_jvim834-bib-0003","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrc1949","article-title":"Cysteine cathepsins: Multifunctional enzymes in cancer","volume":"6","author":"Mohamed","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2026020303573369600_jvim834-bib-0004","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1172\/JCI42918","article-title":"Specialized roles for cysteine cathepsins in health and disease","volume":"120","author":"Reiser","year":"2010","journal-title":"J Clin Invest"},{"key":"2026020303573369600_jvim834-bib-0005","doi-asserted-by":"crossref","first-page":"12517","DOI":"10.1074\/jbc.271.21.12517","article-title":"Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification","volume":"271","author":"Bossard","year":"1996","journal-title":"J Biol Chem"},{"key":"2026020303573369600_jvim834-bib-0006","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","article-title":"Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice","volume":"95","author":"Saftig","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026020303573369600_jvim834-bib-0007","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect","volume":"26","author":"Eisman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2026020303573369600_jvim834-bib-0008","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3816\/CBC.2010.n.059","article-title":"The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: Results of a 4-week, double-blind, randomized, controlled trial","volume":"10","author":"Jensen","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"2026020303573369600_jvim834-bib-0009","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","article-title":"A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden","volume":"67","author":"Le Gall","year":"2007","journal-title":"Cancer Res"},{"key":"2026020303573369600_jvim834-bib-0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2009.60","article-title":"Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: Two double-blind, randomized, placebo-controlled phase I studies","volume":"86","author":"Stoch","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"2026020303573369600_jvim834-bib-0011","first-page":"5386","article-title":"The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma","volume":"57","author":"Littlewood-Evans","year":"1997","journal-title":"Cancer Res"},{"key":"2026020303573369600_jvim834-bib-0012","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/jid.2008.63","article-title":"Cathepsin K in melanoma invasion","volume":"128","author":"Quintanilla-Dieck","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2026020303573369600_jvim834-bib-0013","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0002-9440(10)63323-8","article-title":"Cathepsin K is the principal protease in giant cell tumor of bone","volume":"165","author":"Lindeman","year":"2004","journal-title":"Am J Pathol"},{"key":"2026020303573369600_jvim834-bib-0014","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1359\/jbmr.2003.18.2.222","article-title":"Cathepsin K mRNA and protein expression in prostate cancer progression","volume":"18","author":"Brubaker","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2026020303573369600_jvim834-bib-0015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0945-053X(00)00124-4","article-title":"Cysteine proteinases in chondrosarcomas","volume":"19","author":"Soderstrom","year":"2001","journal-title":"Matrix Biol"},{"key":"2026020303573369600_jvim834-bib-0016","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mc.20362","article-title":"Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis","volume":"47","author":"Husmann","year":"2008","journal-title":"Mol Carcinog"},{"key":"2026020303573369600_jvim834-bib-0017","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1939-1676.2008.0221.x","article-title":"Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain","volume":"23","author":"Fan","year":"2009","journal-title":"J Vet Intern Med"},{"key":"2026020303573369600_jvim834-bib-0018","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1939-1676.2008.0046.x","article-title":"The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis","volume":"22","author":"Fan","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026020303573369600_jvim834-bib-0019","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1939-1676.2007.tb02986.x","article-title":"Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain","volume":"21","author":"Fan","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020303573369600_jvim834-bib-0020","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2460\/javma.2004.225.1567","article-title":"Stereotactic radiosurgery for treatment of osteosarcomas involving the distal portions of the limbs in dogs","volume":"225","author":"Farese","year":"2004","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303573369600_jvim834-bib-0021","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1740-8261.1999.tb00385.x","article-title":"Palliative radiotherapy of appendicular osteosarcoma in 95 dogs","volume":"40","author":"Ramirez","year":"1999","journal-title":"Vet Radiol Ultrasound"},{"key":"2026020303573369600_jvim834-bib-0022","doi-asserted-by":"crossref","first-page":"13955","DOI":"10.1074\/jbc.272.21.13955","article-title":"Autocatalytic activation of human cathepsin K","volume":"272","author":"McQueney","year":"1997","journal-title":"J Biol Chem"},{"key":"2026020303573369600_jvim834-bib-0023","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.bone.2005.10.017","article-title":"Human osteoblasts produce cathepsin K","volume":"38","author":"Mandelin","year":"2006","journal-title":"Bone"},{"key":"2026020303573369600_jvim834-bib-0024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ard.2002.005256","article-title":"Metabolic activation stimulates acid secretion and expression of matrix degrading proteases in human osteoblasts","volume":"63","author":"George","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2026020303573369600_jvim834-bib-0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00223-004-0172-3","article-title":"Osteoblast-like cells complete osteoclastic bone resorption and form new mineralized bone matrix in vitro","volume":"75","author":"Mulari","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"2026020303573369600_jvim834-bib-0026","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00218081","article-title":"Phagocytosis of different matrix components by different cell types at bone-forming sites in cultured mouse calvariae","volume":"245","author":"Takahashi","year":"1986","journal-title":"Cell Tissue Res"},{"key":"2026020303573369600_jvim834-bib-0027","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0003-9969(86)90101-9","article-title":"An ultrastructural study of phagocytosis in bone by osteoblastic cells from fetal mouse calvaria in vitro","volume":"31","author":"Takahashi","year":"1986","journal-title":"Arch Oral Biol"},{"key":"2026020303573369600_jvim834-bib-0028","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.me.42.020191.000313","article-title":"Growth factors and cytokines in bone cell metabolism","volume":"42","author":"Canalis","year":"1991","journal-title":"Annu Rev Med"},{"key":"2026020303573369600_jvim834-bib-0029","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00003086-199102000-00004","article-title":"Bone growth factors","volume":"263","author":"Mohan","year":"1991","journal-title":"Clin Orthop Relat Res"},{"key":"2026020303573369600_jvim834-bib-0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1615\/CritRevEukarGeneExpr.v10.i2.50","article-title":"Molecular mechanisms of tumor-bone interactions in osteolytic metastases","volume":"10","author":"Chirgwin","year":"2000","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"2026020303573369600_jvim834-bib-0031","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/01.blo.0000093055.96273.69","article-title":"Transforming growth factor-beta in osteolytic breast cancer bone metastases","volume":"415","author":"Guise","year":"2003","journal-title":"Clin Orthop Relat Res"},{"key":"2026020303573369600_jvim834-bib-0032","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.biopha.2007.07.001","article-title":"Circulating cathepsin K and cystatin C in patients with cancer related bone disease: Clinical and therapeutic implications","volume":"62","author":"Tumminello","year":"2008","journal-title":"Biomed Pharmacother"},{"key":"2026020303573369600_jvim834-bib-0033","first-page":"1","article-title":"Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease","volume":"2","author":"Meier","year":"2006","journal-title":"Clin Lab"},{"key":"2026020303573369600_jvim834-bib-0034","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.maturitas.2009.09.011","article-title":"Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate","volume":"64","author":"Munoz-Torres","year":"2009","journal-title":"Maturitas"},{"key":"2026020303573369600_jvim834-bib-0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/gme.0b013e3181271873","article-title":"Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women","volume":"15","author":"Prezelj","year":"2008","journal-title":"Menopause"},{"key":"2026020303573369600_jvim834-bib-0036","first-page":"335","article-title":"Urine N-telopeptide excretion in dogs with appendicular osteosarcoma","volume":"20","author":"Lacoste","year":"2006","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2011.00834.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/26\/1\/126\/66683465\/jvim834.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/26\/1\/126\/66683465\/jvim834.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:57:45Z","timestamp":1770109065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/26\/1\/126\/8451619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2011.00834.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,1]]},"published":{"date-parts":[[2012,1,1]]}}}